Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model

Journal of Cellular Biochemistry

Volumn 69, Issue 3, 1998, Pages 271-281

  Gleave, Martin E ^a,b,c   Sato, Naohide ^b   Sadar, Marianne ^b   Yago, Virginia ^b   Bruchovsky, Nicholas ^a,b   Sullivan, Lorne ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Butyrate; Isobutyramide; LNCaP; Prostate cancer

Indexed keywords

BUTYRIC ACID DERIVATIVE; ISOBUTYRAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; GAS CHROMATOGRAPHY; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR DIFFERENTIATION; TUMOR MODEL;

ADMINISTRATION, ORAL; AMIDES; ANDROGENS; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CELL DIVISION; GENE EXPRESSION REGULATION, NEOPLASTIC; HALF-LIFE; HUMANS; MALE; MICE; ORCHIECTOMY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0032104814     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4644(19980601)69:3<271::AID-JCB5>3.0.CO;2-O     Document Type: Article

References (41)

1. Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckley AR, Sullivan LD (1993): Effects of intermittent androgen suppression on androgen-dependent tumours: Apoptosis and serum prostate specific antigen. Cancer 71:2782-2790.
2. Bruchovsky N, Rennie PS, Coldman AJ, Goldenberg SL, To M, Lawson D (1990): Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 50:2275-2282.
3. Candido EPM, Reeves R, Davie JR (1978) Sodium butyrate inhibits histone acetylation in cultured cells. Cell 14:105-113.
4. Carvalho L, Foulkes K, Mickey DD (1989): Effect of DMSO and DFMO on rat prostate tumor growth. Prostate 15: 123-133.
5. Dahiya R, Zhang DY, Ho RJ, PC Haughney, Hayward SW, Cunha GR, Narayan P (1995) Regression of LNCaP human prostate tumr xenografts in athymic nude mice by 13-cis-retinoic acid and androgen ablation. Biochem Mol Biol Int 35:487-498.
6. Dairkee SH, Glaser DA (1982): Dimethyl sulfoxide affects colony morphology on agar and alters distribution of glycosaminoglycans and fibronectin. Proc Natl Acad Sci U S A 79:6927-6931.
7. Denis L, Murphy GP (1993): Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer 72(Suppl):3888-3895.
8. Dover GJ, Brusilow S, Samid D (1992): Increased fetal hemoglobin in patients receiving sodium 4-phenylbutyrate. N Engl J Med 327:569-570.
9. Eisenberger MA, Bezerdjian L, Kalash S (1987): A critical assessment of the role of chemotherapy for endocrine-resistant prostatic carcinoma. Urol. Clin. North Am. 14: 695-706.
10. Figg WD, Walls RG, Cooper MR, Thibault A, Sartor O, McCall NA, Myers CE, Samid D (1994): In vitro antitumor effect of hydroxyurea on hormone-refractory prostate cancer cells and its potentiation by phenylybutyrate. Anticancer Drugs 5:336-342.
11. Fuchs E, Green H (1981): Regulation of terminal differentiation of cultured human keratinocytes by vitamin A. Cell 25:617-625.
12. Glauber JG, Wandersee NJ, Little JA, Ginder GD (1991): 5× flanking sequences mediate butyrate stimulation of embryonic globin gene expression in adult erythroid cells. Mol Cell Biol 11:4690-4697.
13. Gleave ME, Hsieh JT, Gao C, von Eschenbach AC, Chung LWK (1991): Acceleration of human prostate carcinoma growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res 51:3753-3761.
14. Gleave ME, Hsieh JT, Wu H-C, Chung LWK (1992): Serum PSA levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res 52:1598-1605.
15. Gleave ME, Sato N, Rennie P, Bruchovsky N (1996): Prevention of LNCaP prostate tumour growth and progression by isobutyramide, and orally available butyrate analogue. J Urol 155:515A.
16. Gleave ME (1997): Experimental animal models for prostate cancer. In Lange P, Scher H, Ragavahn O (eds): "Genitourinary Oncology." New York: Lippencott, pp. 367-378.
17. Higgins PJ, O'Donnell PV (1982): Dimethylsulfoxide-induced alterations in the growth properties and protein composition of in vitro-propagated murine hepatoma cells. Oncology 39:325-330.
18. Horoszewicz J Leong S, Chu T, Wajsman Z, Freedman M, Papsidero L, Kim U, Chai LS, Kakati S, Arya SK, Sandberg AA (1980): The LNCaP cell line - a new model for studies on human prostatic carcinoma. Prog Clin Biol Res 37:115-132.
19. Hsieh JT, Wu H-C, Gleave ME, von Eschenbach AC, Chung LWK (1993): Autocrine regulation of prostate-specific antigen gene expression in human prostate cells. Cancer Res 53:2852-2857.
20. Kaneski CR, Constantopoulos G, Brady RO (1991): Effect of DMSO on the proliferation and glycosaminoglycan synthesis of rat prostate adenocarcinoma cells (PAIII) in vitro: solation and characterization of DMSO-resistant cells. Prostate 18:47-58.
21. Karin M (1995): The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem 270:16483-16486.
22. Kijima M, Yoshida M, Sugita K, Horinouchi S, Beppu T (1993): Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J Biol Chem 268:22429-22435.
23. Lea MA, Tulsyan N (1995): Disconcordant effects of butyrate analogues on erythroleukemia cell proliferation, differentiation, and histone deacetylase. Anticancer Res 15:879-884.
24. Lundwall Å, Lilja H (1987): Molecular cloning of human prostate specific antigen cDNA. FEBS Lett. 214:317-322.
25. McDonnell T, Troncoso P, Brisbay M, Logothetis C, Chung L, Hsieh JT, Tu SM, Campbell ML (1992): Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52:6940-6944.
26. Nakagawa T, Nelkin BD, Baylin SB, deBustros A (1988): Transcriptional and posttransciptional modulation of calcitonin gene expression by sodium n-butyrate in cultured human medullary thyroid carcinoma. Cancer Res 48: 2096-2100.
27. Norton VG, Imai BS, Yau P, Bradbury EM (1989): Histone acetylation reduces nucleosome core particle linking number change. Cell 57:449-457.
28. Oesterling JE (1991): Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145:907-923.
29. Perrine SP, Dover GH, Daftari P, Walsh CT, Jin Y, Mays A, Faller DV (1994): Isobutyramide, an orally bioavailable butyrate analogue, stimulates fetal globin bene expression in vitro and in vivo. Br J Hematol 88:555-561.
30. Pollard M, Luckert PH, Sporn MB (1991): Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxyphenyl) retinamide. Cancer Res 51:3610-3611.
31. Ratko TA, Detrisac CJ, Dinger NM, Thomas CF, Kelloff GJ, Moon RC (1989): Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats. Cancer Res 49:4472-4476.
32. Riegman PHJ, Vlietstra RJ, van der Korput JAGM, Brinkmann AO, Trapman J (1991): The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol Endocrinol 5:1921-1930.
33. Samid D, Shack S, Myers CE (1993): Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacologic concentrations of phenylacetate. J Clin Invest 91:2288-2295.
34. Sato N, Gleave ME, Goldenberg SL, Bruchovsky N, Rennie P, Sullivan LD (1996): Intermittent androgen suppression delays time to androgen-indepenent progression in the LNCaP prostate tumour model. J. Steroid Biochem Mol Biol 58:139-146.
35. Sellins K, Cohen J (1997): Gene induction by gamma-irradiation leads to DNA fragmentation in lymphocytes. J Immunol 39:3199-3206.
36. Slawin K, Kadmon D, Park SH, Scardino PT, Anzano M, Sporn MB, Thompson TC (1991): Dietary fenretinide, a syntheitic retinoid, decreases the tumor incidence and the tumor mass of ras+myc-induced carcinomas in the mouse prostate reconstitution model system. Cancer Res 53:4461-4465.
37. Svanholm H, Hrder M (1988): Clinical application of prostatic markers: I. Classification of prostatic tumors using immunohistochemical techniques. Scand. J. Urol. Nephrol. 107(Suppl):65-70.
38. Trachtenberg J, Walsh PC (1982): Correlation of prostatic nuclear androgen receptor content with duration of response and survival following hormonal therapy in prostatic cancer. J Urol 127:466-471.
39. Watkins LF, Brattain MG, Levine AE (1988): Modulation of a high molecular weight form of transforming growth factor-alpha in human colon carcinoma cell lines. Cancer Lett 40:59-70.
40. Waxman S, Scher W, Scher BM (1986): Basic principles for utilizing combination differentiation agents. Cancer Detect Prev 9:395-407.
41. Westin EH, Wong-Staal F, Gelmann EP, Dalla Favera R, Papas TS, Lautenberger JA, Eva A, Reddy EP, Tronick SR, Aaronson SA, Gallo RC (1982): Expression of cellular homologues of retroviral oncogenes in human hematopoietic cells. Proc Natl Acad Sci U S A 79:2490-2494.